Biomarkers as Surrogates for Coronary Endothelial Dysfunction in Patients With Nonobstructive Coronary Artery Disease.
作者信息
Vani Anish, Schwartzbard Arthur, Weintraub Howard S
机构信息
1 Division of Cardiology New York University School of Medicine New York NY.
出版信息
J Am Heart Assoc. 2018 Aug 7;7(15):e010166. doi: 10.1161/JAHA.118.010166.
Abstract
摘要
相似文献
1
Biomarkers as Surrogates for Coronary Endothelial Dysfunction in Patients With Nonobstructive Coronary Artery Disease.
J Am Heart Assoc. 2018 Aug 7;7(15):e010166. doi: 10.1161/JAHA.118.010166.
2
Local Production of Soluble Urokinase Plasminogen Activator Receptor and Plasminogen Activator Inhibitor-1 in the Coronary Circulation Is Associated With Coronary Endothelial Dysfunction in Humans.
J Am Heart Assoc. 2018 Aug 7;7(15):e009881. doi: 10.1161/JAHA.118.009881.
3
Plasma soluble urokinase-type plasminogen activator receptor level is independently associated with coronary microvascular function in patients with non-obstructive coronary artery disease.
Atherosclerosis. 2015 Mar;239(1):55-60. doi: 10.1016/j.atherosclerosis.2014.12.025. Epub 2014 Dec 20.
4
Soluble urokinase-type plasminogen activator receptor: a useful biomarker for coronary artery disease and clinical outcomes?
J Am Heart Assoc. 2014 Oct 23;3(5):e001431. doi: 10.1161/JAHA.114.001431.
5
Increased Inflammatory Activity in Patients 3 Months after Myocardial Infarction with Nonobstructive Coronary Arteries.
Clin Chem. 2019 Aug;65(8):1023-1030. doi: 10.1373/clinchem.2018.301085. Epub 2019 May 9.
6
Prognostic value of soluble urokinase-type plasminogen activator receptor in coronary artery disease: A meta-analysis.
Eur J Clin Invest. 2022 Dec;52(12):e13867. doi: 10.1111/eci.13867. Epub 2022 Sep 8.
7
Lack of correlation between noninvasive stress tests and invasive coronary vasomotor dysfunction in patients with nonobstructive coronary artery disease.
Circ Cardiovasc Interv. 2009 Jun;2(3):237-44. doi: 10.1161/CIRCINTERVENTIONS.108.841056. Epub 2009 May 8.
8
SuPAR is associated with death and adverse cardiovascular outcomes in patients with suspected coronary artery disease.
Scand Cardiovasc J. 2020 Dec;54(6):339-345. doi: 10.1080/14017431.2020.1762917. Epub 2020 May 13.
9
Predicting Mortality in African Americans With Type 2 Diabetes Mellitus: Soluble Urokinase Plasminogen Activator Receptor, Coronary Artery Calcium, and High-Sensitivity C-Reactive Protein.
J Am Heart Assoc. 2018 May 1;7(9):e008194. doi: 10.1161/JAHA.117.008194.
10
Soluble urokinase plasminogen activator receptor: a risk factor for carotid plaque, stroke, and coronary artery disease.
Stroke. 2014 Jan;45(1):18-23. doi: 10.1161/STROKEAHA.113.003305. Epub 2013 Nov 19.
本文引用的文献
1
Local Production of Soluble Urokinase Plasminogen Activator Receptor and Plasminogen Activator Inhibitor-1 in the Coronary Circulation Is Associated With Coronary Endothelial Dysfunction in Humans.
J Am Heart Assoc. 2018 Aug 7;7(15):e009881. doi: 10.1161/JAHA.118.009881.
2
Will Reducing Inflammation Reduce Vascular Event Rates?
JACC Cardiovasc Imaging. 2018 Feb;11(2 Pt 2):317-319. doi: 10.1016/j.jcmg.2017.10.001. Epub 2017 Oct 18.
3
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.
N Engl J Med. 2017 Sep 21;377(12):1119-1131. doi: 10.1056/NEJMoa1707914. Epub 2017 Aug 27.
4
suPAR: A New Biomarker for Cardiovascular Disease?
Can J Cardiol. 2015 Oct;31(10):1293-302. doi: 10.1016/j.cjca.2015.03.023. Epub 2015 Mar 25.
5
2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):2889-934. doi: 10.1016/j.jacc.2013.11.002. Epub 2013 Nov 12.
6
Automated preoperative assessment of endothelial dysfunction and risk stratification for perioperative myocardial injury in patients undergoing non-cardiac surgery.
Br J Anaesth. 2014 Jan;112(1):47-56. doi: 10.1093/bja/aet354. Epub 2013 Oct 29.
7
Plasminogen activator inhibitor-1 and the circadian clock in metabolic disorders.
Clin Exp Hypertens. 2009 May;31(3):208-19. doi: 10.1080/10641960902822468.
8
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
N Engl J Med. 2008 Nov 20;359(21):2195-207. doi: 10.1056/NEJMoa0807646. Epub 2008 Nov 9.
9
Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome.
Vasc Health Risk Manag. 2005;1(3):183-98.
10
Endothelial function: cardiac events.
Circulation. 2005 Jan 25;111(3):363-8. doi: 10.1161/01.CIR.0000153339.27064.14.
Zotero 插件